CRISPR-Cas13b

CRISPR-Cas13b

Nucleic acid editing technology that targets RNA and is being developed as a tool for editing pathogenic mutations in RNA transcripts.

All edits

Edits on 15 Nov, 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 15 Nov, 2018
Edits made to:
Article (+3/-3 characters)
Article

RNA Editing for Programmable A to I Replacement (REPAIR) was developed by Feng Zhang at the Broad Institute at MIT and Harvard based on CRISPR-Cas13 was developed by Zhang’s lab to edit RNA transcripts with pathogenic mutations . The Cas13b ortholog from the bacterium Prevotella sp. P5–125 was engineered to not cleave RNA (dCas13b) and fused to an adensosine deaminase enzyme which changes A to I in targeted spot on an RNA transcript as determined by the user supplied guide RNA. Zhang’s team used REPAIR to correct RNA transcripts in cell lines from patients with mutations causing Fanconi anemia and X-linked Nephrogenic diabetes insipidus. The REPAIR system is engineered for viral delivery into cells. There are less sequence constraints for CRISPR-Cas13 RNA editing than for CRISPR-Cas9 DNADNA editing, making it more flexible. However since the REPAIR system targets RNA not DNA, effects are temporary. Zheng's group suggests it would be suitable to treat diseases with acute phases like inflammation or modify proteins in the disease pathway to slow disease progression.

Edits on 14 Nov, 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 14 Nov, 2018
Edits made to:
Related Topics (+1 topics)
Related Topics
Edits on 29 Oct, 2018
Meredith Hanel"Image thumbnail: from Front. Genet., 18 April 2018 | https://doi.org/10.3389/fgene.2018.00134"
Meredith Hanel edited on 29 Oct, 2018
Edits made to:
Topic thumbnail

CRISPR-Cas13b

Nucleic acid editing technology that targets RNA and is being developed as a tool for editing pathogenic mutations in RNA transcripts.

Meredith Hanel
Meredith Hanel edited on 29 Oct, 2018
Edits made to:
Article (+12/-12 characters)
Article

RNA Editing for Programmable A to I Replacement (REPAIR) was developed by Feng Zhang at the Broad Institute at MIT and Harvard based on CRISPR-Cas13CRISPR-Cas13 was developed by Zhang’s lab to edit RNA transcripts with pathogenic mutations . The Cas13b ortholog from the bacterium Prevotella sp. P5–125 was engineered to not cleave RNA (dCas13b) and fused to an adensosine deaminase enzyme which changes A to I in targeted spot on an RNA transcript as determined by the user supplied guide RNA. Zhang’s team used REPAIR to correct RNA transcripts in cell lines from patients with mutations causing Fanconi anemia and X-linked Nephrogenic diabetes insipidus. The REPAIR system is engineered for viral delivery into cells. There are less sequence constraints for CRISPR-Cas13 RNA editing than for CRISPR-Cas9 DNA editing, making it more flexible. However since the REPAIR system targets RNA not DNA, effects are temporary. Zheng's group suggests it would be suitable to treat diseases with acute phases like inflammation or modify proteins in the disease pathway to slow disease progression.

Meredith Hanel
Meredith Hanel edited on 29 Oct, 2018
Edits made to:
Description (+134 characters)
Article (+1080 characters)
Categories (+3 topics)
Related Topics (+2 topics)

CRISPR-Cas13b

Nucleic acid editing technology that targets RNA and is being developed as a tool for editing pathogenic mutations in RNA transcripts.

Article

RNA Editing for Programmable A to I Replacement (REPAIR) was developed by Feng Zhang at the Broad Institute at MIT and Harvard based on CRISPR-Cas13 was developed by Zhang’s lab to edit RNA transcripts with pathogenic mutations . The Cas13b ortholog from the bacterium Prevotella sp. P5–125 was engineered to not cleave RNA (dCas13b) and fused to an adensosine deaminase enzyme which changes A to I in targeted spot on an RNA transcript as determined by the user supplied guide RNA. Zhang’s team used REPAIR to correct RNA transcripts in cell lines from patients with mutations causing Fanconi anemia and X-linked Nephrogenic diabetes insipidus. The REPAIR system is engineered for viral delivery into cells. There are less sequence constraints for CRISPR-Cas13 RNA editing than for CRISPR-Cas9 DNA editing, making it more flexible. However since the REPAIR system targets RNA not DNA, effects are temporary. Zheng's group suggests it would be suitable to treat diseases with acute phases like inflammation or modify proteins in the disease pathway to slow disease progression.

Categories
Related Topics
Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 29 Oct, 2018
Edits made to:
Topic thumbnail

 CRISPR-Cas13b

Nucleic acid editing technology that targets RNA and is being developed as a tool for editing pathogenic mutations in RNA transcripts.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.